3 Undervalued Life Sciences Tools & Services Stocks for Monday, November 11
Discover the top 3 undervalued Life Sciences Tools & Services stocks for Monday, November 11 based on AAII’s Stock Grades.Omar Beirat
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Jack Gilleland
Jack Gilleland
| Share Statistics | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12.2 | $3,763.8 | 8% |
|
| Shares Out (Mil) | 12.0 | 106.8 | 23% |
|
| Institutional Ownership | 99.2% | 89.2% | 85% |
|
| Float (Mil) | 9.5 | 83.6 | 19% |
|
| Beta | na | 1.14 | na |
|
| Avg Daily Volume (000s) | 312 | 1,125 | 50% |
|
| Price Change (52-week) |
(35.8%) | 86.2% | 27% |
|
| Growth | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.4% | 7.5% | 88% |
|
| Net Income (5yr) | 8.5% | (12.1%) | 53% |
|
| EPS (5yr) | 54.0% | 2.1% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.390) | ($2.140) | ($0.970) | |
| Month Ago EPS | ($0.390) | ($2.140) | ($0.970) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.390) | ($2.140) | ($0.970) | |
| Year/Year Chg | (27.8%) | (55.9%) | (89.3%) | |
| Financials | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $31 | $811 | 16% |
|
| Net Income (TTM) (Mil) | ($30) | ($30) | 20% |
|
| EPS (TTM) | ($2.688) | ($0.300) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | $52 | 15% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $2 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $252 | 25% |
|
| Enterprise Value (Q1) (Mil) | $13 | $3,646 | 9% |
|
| Valuation | BNGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.50 | 3.63 | 11% |
|
| P/E | na | 36.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.6 | na |
|
| Ratios | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 48.0% | 47.8% | 60% |
|
| Net Margin | (96.9%) | (3.0%) | 8% |
|
| ROA | (48.0%) | (5.4%) | 12% |
|
| ROE | (77.2%) | (5.2%) | 11% |
|
| Liabilities to Assets | 39.1% | 41.5% | 30% |
|
| F-Score | 3 | 5 | 18% |
|
Bionano Genomics, Inc. did not pass any screens on 11/12/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors